Amicus Therapeutics. has filed a patent for methods to treat Fabry disease in patients with specific mutations in a-galactosidase A. The treatment involves administering migalastat every other day, with a specific dosage mentioned. Additionally, a claim for a molecule comprising migalastat bound to the mutated protein is included. GlobalData’s report on Amicus Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Amicus Therapeutics, Human telomerase RT biomarker was a key innovation area identified from patents. Amicus Therapeutics's grant share as of January 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of fabry disease with migalastat for specific mutations
A patent application (Publication Number: US20230381164A1) discloses a molecule comprising migalastat bound to an a-galactosidase A protein with specific HEK assay amenable mutations. These mutations include D55G, H125Y, Q157H, L166S, N215I, K240N, G261R, L275V, N278Y, W287L, K308E, and P343T. The molecule aims to enhance the stability of the protein compared to its naturally-occurring form.
Furthermore, the patent application describes an a-galactosidase A protein with the same mutations bound to migalastat, resulting in increased stability compared to the wild-type protein. The mutations in this protein include D55G, H125Y, Q157H, L166S, N215I, K240N, G261R, L275V, N278Y, W287L, K308E, and P343T. This innovation could have implications for the treatment of conditions related to a-galactosidase A deficiency.
To know more about GlobalData’s detailed insights on Amicus Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
